Worland PJ - Search Results

1

Potent inhibition of CDC2 kinase activity by the flavonoid L86-8275.

Losiewicz MD, Carlson BA, Kaur G, Sausville EA, Worland PJ. Losiewicz MD, et al. Among authors: worland pj. Biochem Biophys Res Commun. 1994 Jun 15;201(2):589-95. doi: 10.1006/bbrc.1994.1742. Biochem Biophys Res Commun. 1994. PMID: 8002990

2

Selective effects of mastoparan analogs: separation of G-protein-directed and membrane-perturbing activities.

Danilenko M, Worland P, Carlson B, Sausville EA, Sharoni Y. Danilenko M, et al. Biochem Biophys Res Commun. 1993 Nov 15;196(3):1296-302. doi: 10.1006/bbrc.1993.2393. Biochem Biophys Res Commun. 1993. PMID: 8250884

3

Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275.

Kaur G, Stetler-Stevenson M, Sebers S, Worland P, Sedlacek H, Myers C, Czech J, Naik R, Sausville E. Kaur G, et al. J Natl Cancer Inst. 1992 Nov 18;84(22):1736-40. doi: 10.1093/jnci/84.22.1736. J Natl Cancer Inst. 1992. PMID: 1279187

4

Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells.

Sommers CL, Walker-Jones D, Heckford SE, Worland P, Valverius E, Clark R, McCormick F, Stampfer M, Abularach S, Gelmann EP. Sommers CL, et al. Cancer Res. 1989 Aug 1;49(15):4258-63. Cancer Res. 1989. PMID: 2472876

5

Flavopiridol (L86 8275; NSC 649890), a new kinase inhibitor for tumor therapy.

Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A, Sausville E. Sedlacek H, et al. Int J Oncol. 1996 Dec;9(6):1143-68. doi: 10.3892/ijo.9.6.1143. Int J Oncol. 1996. PMID: 21541623

6

Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase.

De Azevedo WF Jr, Mueller-Dieckmann HJ, Schulze-Gahmen U, Worland PJ, Sausville E, Kim SH. De Azevedo WF Jr, et al. Among authors: worland pj. Proc Natl Acad Sci U S A. 1996 Apr 2;93(7):2735-40. doi: 10.1073/pnas.93.7.2735. Proc Natl Acad Sci U S A. 1996. PMID: 8610110 Free PMC article.

7

UCN-01: a potent abrogator of G2 checkpoint function in cancer cells with disrupted p53.

Wang Q, Fan S, Eastman A, Worland PJ, Sausville EA, O'Connor PM. Wang Q, et al. Among authors: worland pj. J Natl Cancer Inst. 1996 Jul 17;88(14):956-65. doi: 10.1093/jnci/88.14.956. J Natl Cancer Inst. 1996. PMID: 8667426

8

Structure-activity relationship studies of flavopiridol analogues.

Murthi KK, Dubay M, McClure C, Brizuela L, Boisclair MD, Worland PJ, Mansuri MM, Pal K. Murthi KK, et al. Among authors: worland pj. Bioorg Med Chem Lett. 2000 May 15;10(10):1037-41. doi: 10.1016/s0960-894x(00)00156-6. Bioorg Med Chem Lett. 2000. PMID: 10843211

9

Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.

Carlson BA, Dubay MM, Sausville EA, Brizuela L, Worland PJ. Carlson BA, et al. Among authors: worland pj. Cancer Res. 1996 Jul 1;56(13):2973-8. Cancer Res. 1996. PMID: 8674031

10

Apoptosis in 7-hydroxystaurosporine-treated T lymphoblasts correlates with activation of cyclin-dependent kinases 1 and 2.

Wang Q, Worland PJ, Clark JL, Carlson BA, Sausville EA. Wang Q, et al. Among authors: worland pj. Cell Growth Differ. 1995 Aug;6(8):927-36. Cell Growth Differ. 1995. PMID: 8547221

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results